Penumbra (PEN) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Penumbra (PEN) do?
Penumbra Inc (PEN) is a U.S.-listed company in Healthcare (Medical Devices). What it does: Manufactures aspiration thrombectomy systems and neurovascular access tools for hospital catheterization labs. Engineers computer-assisted aspiration systems that remove blood clots from neurovascular and peripheral blood vessels. It is worth $12.61B on the market and sold $1.56B over the last year.
- Market cap
- $12.61B
- P/E ratio
- 80.6×
- Annual sales
- $1.56B
- Sector
- Healthcare
- Industry
- Medical Devices
- Brief updated
- Nov 14, 2026
Brands and businesses behind PEN
- Lightning: Computer-assisted clot removal system sold to vascular specialists for stroke and embolism treatments.
- Indigo System: Aspiration thrombectomy device sold to hospitals for clearing clots in peripheral arteries and veins.
- Ruby Coil: Detachable platinum coil implant used by neurosurgeons to pack and seal brain aneurysms.
- REAL System: Virtual reality therapy hardware and software leased to rehabilitation clinics for patient physical therapy.
PEN’s flags, in plain English
Each flag is a number from Penumbra’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 14, 2026.
Stupid Cash
Can pay this year's bills 5.9 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.
Low debt
Low debt, only 13% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.
Wide Gross Margin
Gross margin of 66.7% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Priced for Perfection
Priced at 80.6 times its yearly profit, so a lot of growth is already expected. The share price already assumes strong results, so news that is merely good can still send it down.
2 more green flags open with the free trial. Try it free for 7 days.
Questions about PEN
How big is Penumbra?
Penumbra’s market cap is $12.61B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $1.56B: what customers paid the company over the last year, before any costs.
What is PEN’s P/E ratio?
PEN’s P/E ratio is 80.6×. Investors pay about 80.6 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.
What could go wrong with PEN?
Large cardiovascular device makers sell rival thrombectomy tools directly to the same hospital catheter labs. That is one risk on Penumbra’s card. Its first risk flag is Priced for Perfection, explained above. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Penumbra’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. PEN’s filings on SEC.gov. The Margin Monkey is research, not advice.
